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ALMOST any stage of inflammatory and immunological
responses is affected by hormone actions. This provides
the basis for the suggestion that hormones act as modula-
tors of the host reaction against trauma and infection.
Specific hormone receptors are detected in the reactive
structures in inflamed areas and binding of hormone
molecules to such receptors results in the generation of
signals that influence cell functions relevant for the devel-
opment of inflammatory responses. Diversity of hormonal
functions accounts for recognized pro- and anti-inflamma-
tory effects exerted by these substances. Most hormone
systems are capable of influencing inflammatory events.
Insulin and glucocorticoids, however, exert direct regula-
tory effects at concentrations usually found in plasma.
Insulin is endowed with facilitatory actions on vascular
reactivity to inflammatory mediatQrs and inflammatory
cell functions. Increased concentrations of circulating glu-
cocorticoids at the early stages of inflammation results in
downregulation of inflammatory responses. Oestrogens
markedly reduce the response to injury in a variety of
experimental models. Glucagon and thyroid hormones
exert indirect anti-inflammatory effects mediated by the
activity of the adrenal cortex. Accordingly, inflammation
is not only merely a local response, but a hormone-
controlled process.
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Introduction
An impressive challenge imposed by external
factors to an organism in the animal kingdom,
particularly in vertebrates, is the reaction to
emergency conditions, such as trauma and infec-
tion. To deal efficiently with the corresponding
demands, the organism activates a narrowly
regulated set of events, characteristic of the in-
flammatory response. These include functional
alterations of microvessels, migration of haemato-
genous cells to the injured area, phagocytosis by
competent cells and local pain. Recruitment of
components of the immune system leads to the
amplification of the reaction.
Inflammation was considered a disease until
Hunter in 1794, described it as a nonspecific
response evoked by all manner of injury and both
purposeful and beneficial in nature. This view was
strongly supported by the results of Metchnikoff’s
investigations on the comparative pathology of
inflammation dating from the end of the nineteenth
century. The beneficial character of the response,
however, was not easily assimilated at the time,
inflammation being rather regarded as a passive and
deleterious reaction, of no benefit to the host.
Experiments in which pyogenic bacteria were used
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as the inflammatory stimulus, convincingly illu-
strate the defensive aspect of inflammation. In these
experiments, recognized components of the early
inflammatory reaction were blocked by systemic
shock, local ischaemia, or administration of
anticomplementary substances, and the effect of a
modified host resistance on the final size of the
developing bacterial lesion was compared to the
lesion size in control animals. In all cases, the
injection of bacteria into the dermis during periods
of shock or ischaemia, or following the administra-
tion of anticomplementary substances resulted in
maximal lesions substantially larger and more
severe than the control lesions,am The results
indicate that there is an early period in which the
integrity of the response against injury is essential
to prevent or limit the intensity of a future lesion,
and stress the defensive role of inflammation.
A most significant aspect in earlier views on
inflammation is the notion that the response is a
pattern reaction developing regardless of the cause.
Accordingly, any type of injury tends to evoke a
similar response of the organism. It was from such
notion that the idea of the response being mediated
by endogenously mobilized active materialsthe
inflammatory mediators--arose. Ideally, a potential
inflammatory mediator should have the appropriate
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properties to bring about that part of the
inflammatory response for which it is deemed to be
responsible; it should be demonstrably present for
a phase of the inflammatory response; and if it is
possible to deplete the tissues of the mediator, this
should also lead to a suppression of the
inflammatory event for which it is responsible. 5’6
From numerous observations, generally it has
been concluded that, in addition to chemical
mediators, the inflammatory response is under the
influence of substances of diverse origin which are
capable of modulating its development. It is
possible to identify local tissue factors, plasma
factors, neurogenic factors, and hormones which
7<0 act as modulators of the inflammatory process.
These substances provide the basis for the
occurrence of regulatory mechanisms responsible
for a fine-tune adjustment of the host response in
accordance with the intensity of the damage
inflicted. Were it only merely a local response,
inflammation would hardly be so effective as a
defensive reaction against injury.
Hormone studies from the early decades in this
century, clearly indicate that many biological
systems are subject to control by hormone actions.
Binding of hormone molecules to specific receptors
in target structures results in the generation of
signals that influence cell functions. Specific
ho.rmone receptors are detected in the reactive
structures in inflamed areas and, in most instances,
there is a striking similarity of the binding sites in
those structures and those present in recognized
target cells as far as the apparent aflqnity, specificity,
and kinetics of the interaction are concerned.
Accordingly, hormones can influence cell functions
relevant for the development of inflammatory
responses, including vascular reactivity to inflam-
matory mediators, oriented cell locomotion, particle
ingestion by phagocytes, and microbicidal function.
Granulation tissue formation, healing, and repair
are also affected by the activity of endocrine glands.
Diversity of hormonal functions is likely to account
for the recognized pro- and anti-inflammatory
effects exerted by these substances.
Most hormone systems are capable of influencing
the development of inflammatory reactions.1
Insulin and glucocorticoids, however, appear to
exert direct regulatory eects on the reactive
structures in an inflamed area, at concentrations
usually found in plasma.
The proinflammatory effect of
insulin
The insulin receptor: Insulin occurs throughout the
entire vertebrate kingdom and is probably also
present in many invertebrates. It serves the
essential role of regulating the synthetic phase of
energy metabolism by promoting glucose and
amino acid uptake, glycogen and protein synthesis,
and lipogenesis. The existence of a specific insulin
receptor was postulated as early as 20 years
ago.l-3 The receptor is a heterotetrameric structure
consisting of two -subunits ofM 135 kDa on the
outside of the plasma membrane connected by
disulphide bonds to/-subunits ofM 95 kDa which
are transmembrane proteins. Insulin binding to the
-subunit induces conformational changes which
are transduced to the/-subunit. This leads to the
activation of a tyrosine kinase activity which is
intrinsic to the cytoplasmic domain of the
fl-subunit. Activation of the tyrosine kinase
activity of the insulin receptor is an essential step
in the transduction of an insulin signal across the
plasma membrane of target cells. Signal transduc-
tion on the postkinase level possibly involves
phosphorylation of substrate proteins at tyrosine
residues, activation of serine kinases, and interac-
tion with G-proteins, phospholipases and phospha-
tidylinositol kinases.
4 A large number of agents and
altered physiological conditions are known to affect
insulin binding to target cells. Addition of
catecholamines, glucagon, or glucocorticoids to
cells, as well as the diabetic state and obesity modify
insulin receptor activity.
s-18
Insulin and the endothelial cell: Insulin receptors are
demonstrable on the surface of endothelial cells.
19
Regional dit:ferences, however, are observed in
insulin receptor concentration, as revealed by
insulin binding studies in primary cultures of
endothelial cells. Both arterial and venous en-
dothelial cells possess typical receptors for insulin
on the basis of specifity of binding, curvilinear
Scatchard plots, aflqnity profiles, pH dependence,
and dissociation kinetics. Arterial cells, however,
bind at least 2.5 times more insulin than do venous
cells, whether studied at 4, 24, or 72 h after in vitro
plating.
2 Scanning electron microscopy studies
indicate that overt differences in surface morpho-
logy and surface area do not account for the
differences in insulin binding between the two cell
types. The cause of the marked difference in binding
is not readily apparent. The observation that
endothelial cells from several vascular locations can
also manifest differences in a diverse group of
functional properties, however, suggests that
endothelial cells, from different vascular sites
possess highly specialized and distinct surface
characteristics and functional properties.
2
The characterization of insulin uptake by
microvascular tissues is usually hampered by a lack
of suitable tissue preparations and by the
complexity involved in analysing binding studies in
a tissue with more than one type of cell.
Nevertheless binding of insulin to microvessels
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isolated from adult bovine and neonatal porcine
cerebral cortex is shown to be affected by pH,
temperature, and other physiological conditions in
much the same manner as the binding of this
hormone to liver, adipose tissue, and muscle.
Furthermore, chemical covalent cross-linking of
insulin to its receptor in cerebral microvessels and
the subsequent isolation of the hormone-receptor
complex, indicate that the hormone is found
associated with a polypeptide with a molecular
weight which is indistinguishable from the
-subunit of the liver insulin receptor.
21
The presence of endothelial surface receptors for
insulin may be of physiological significance in
several general ways: insulin could directly
modulate endothelial function; surface receptors for
insulin could play a role in the transfer of insulin
between the circulation and the subendothelial
tissues; insulin bound to the endothelial surface
could be released into the circulation, the
endothelium serving as an additional storage
compartment that would influence blood levels of
insulin,e Therefore, though the mechanism of
glucose entry into vascular endothelial cells is
thought to be independent of the action of insulin,
22
the hormone is likely to influence the activity and
functions of the vascular endothelium. 23’24
Vascular responsiveness in insulin-deficient states: Diabetes
mellitus, as a clinical or experimental entity, at:fects
the microcirculation, as well as large arteries and
occasionally veins. The ability of insulin to restore
altered vascular responsiveness in experimental
diabetes mellitus is an indication that the alterations
are a consequence of the diabetic state. This is
observed not only in preparations of large vessels
from diabetic animals receiving insulin,2s’26 but also
in microvascular beds of insulin-treated diabetic
animals.
Data obtained with tyramine, an indirectly acting
sympathomimetic amine, provide evidence that no
abnormal release of noradrenaline from storage sites
occurs at the early stages of diabetes mellitus.
Furthermore, they indicate that uptake mechanisms
into the adrenergic nerve terminal are unlikely to
be altered since displacement of noradrenaline
requires tyramine uptake. Interaction of noradrena-
line with specific receptors to produce sympathomi-
metic effects is also unaffected as shown by
equivalent arteriolar constrictor responses induced
by the catecolamine in normal and diabetic animals.
In addition, equal concentrations of phentolamine
are capable of blocking such responses in both
groups of animals. Dilatation of arterioles and
venules is observed in normal and diabetic animals
with equivalent doses of acetylcholine, thereby
suggesting that effector mechanisms for vasodila-
tion are also preserved at the early stages of diabetes
mellitus. Accordingly, release of endothelium-
derived relaxing factor (EDRF) by acetycholine
does not appear to be altered, nor does the relaxing
mechanisms in vascular smooth muscle, as shown
by the responses to papaverine, an endothelium-
independent vasodilator.
27 Therefore, if functional
alterations of microvessels are observed at the early
stages of the diabetic state, they are not necessarily
related to any noticeable dysfunction of the
autonomic nervous system. However, 2 months
after the induction of streptozocin diabetes in rats,
a nonspecific decrease in contractile responsiveness
of the mesenteric vascular bed to nerve stimulation,
and to intraluminal noradrenaline can be shown.
The diabetes-evoked depression of responses at this
stage suggests the occurrence of functional changes
in vascular reactivity to which an abnormality in
sympathetic neuronal activity contributes.
28
Norepinephrine evokes a constrictor response of
mesenteric microvessels in situ, the latency of which
is analogous in normal and alloxan diabetic rats.
Histamine and bradykinin are capable of antagoniz-
ing this response in normal but not in diabetic
animals, unless the minimum effective doses are
increased about 20-fold. In contrast, acetylcho-
line and papaverine are equally effective in both
groups of animals. The altered response to
histamine and bradykinin are not directly associated
with hyperglycaemia since fasting renders the
diabetic animals normoglycaemic and yet does not
restore the reactivity of microvessels to these
agents. Previous administration of insulin to
diabetic animals corrects the impaired responses.
The functional changes observed in the responses
to histamine and bradykinin, under these condi-
tions, are unlikely to be associated with a defective
response of the smooth muscle. First, because in
extravascular smooth muscles obtained from either
normal or diabetic animals equivalent responses to
histamine and bradykinin are observed. Secondly,
because concentration-effect curves, constructed
from the response of isolated aortae to noradrena-
line, are similar in normal and diabetic animals,
provided the endothelium is removed. Differences
are only observed in preparations in which the
endothelium is left intact. Since histamine and
bradykinin are potent permeability-increasing
agents in most species, whereas acetylcholine and
papaverine are devoid of such an action, histamine
and bradykinin might antagonize the constrictor
response of microvessels to noradrenaline through
an action on lining endothelial cells resulting in
interendothelial gaps and increased vascular perme-
ability with transitory changes in the composition
of extravascular t:luid.29’30 Induced changes in local
steady-state conditions, if the only from the osmotic
point of view, can affect the reactivity of small
vessels.1 Accordingly, endothelial ceils may play a
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role when vasoactive substances, endowed with
permeability-increasing properties, act on micro-
vessels. That insulin is involved in such events is
suggested by the restorative effect it exerts in
diabetic animals and by the finding that a similar
condition of impaired responses to histamine and
bradykinin is produced in normal animals by the
injection of 2-deoxyglucose, the acute effects of
which are the result of intracellular glucopenia
secondary to inhibition of glucose utilization.
32
The findings are consistent with the view that
functional alterations of microvessels, characteristic
of the diabetic state, involve the vascular
endothelium and that, at least in part, they may be
linked to continuing insulin deficiency.
Insulin and the vascular response to injury: The observations
described above point to the in’volvement of insulin
in events that are important for the development of
inflammatory responses. It is, therefore, expected
that many aspects of inflammation will be affected
by the diabetic state. Edlung and co-workers in
1952 reported in a brief note that alloxan inhibits
the dextran oedema in the rat. The et:fect, however,
was attributed to alloxan itself and not to the
diabetic state. 33 Subsequent studies revealed that
regardless of what the immediate eects of alloxan
may be, decreased inflammatory reactions in alloxan
diabetic animals are obviously related to the diabetic
state, since they can be obtained for several days
following the injection of alloxan and can be
reversed by insulin treatment. Alloxan diabetic rats
fail to present the characteristic cutaneous oedema
(’anaphylactoid’ response) which follows the
intravenous injection of dextran or egg white. The
histamine content of the skin in these animals,
however, is indistinguishable from that of controls.
Pretreatment with insulin restores the ability of the
animals to respond in a normal fashion to the
injection of dextran or egg white. Furthermore,
compound 48/80, a potent histamine releasing
agent, is capable of evoking a shock-like picture of
comparable intensity in alloxan treated and normal
animals, thus indicating that the reduced inflam-
matory response rather reflects a reduced capacity
of the animals to respond to inflammatory
agents.
34 In addition, insulin considerably sensitizes
rats to the dextran anaphylactoid reaction. Ineffec-
tive doses of dextran can initiate the reaction if
given in association with crystalline insulin.s
Light microscope investigation and electron
microscopic studies revealed that microvessels of
alloxan diabetic rats, challenged with histamine or
serotonin, exhibit less labelling by intravenously
injected colloidal carbon particles than do vessels
of normal animals. Insulin corrects this condition
and also potentiates leakage of carbon evoked by
permeability-increasing factors in normal animals.
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The carbon particles label venules almost exclus-
ively and abandon the lumen of leaking vessels
through interendothelial junctions.
6 The vascular
endothelium is highly permeable to water and water
soluble molecules, but normally restricts the
passage of macromolecules. Escape of plasma
proteins in inflammation (or of colloidal carbon
particles as in the experiments referred to above)
apparently depend on a partial ’disconnection’ of
endothelial cells along the intercellular junctions.
Several mechanisms were proposed in the attempt
to explain how the molecules of inflammatory
mediators succeed in creating intercellular gaps in
microvessels through which leakage of macro-
molecules occurs. Contraction of endothelial cells is
still a tenable explanation.
7-41 Insulin through an
action on endothelial cells, might influence the
response of these cells to inflammatory mediators,
thus exerting a facilitatory effect on microvascular
permeability.
This view is supported by the following
observations. The oedema which develops in an
area after local injection of chemical irritants or
application of physical stimuli is reduced when the
animals are rendered diabetic by the administration
of alloxan or streptozocin or by subtotal pancrea-
tectomy. This inhibition is abolished by previous
injection of insulin and is not associated with
increased blood sugar concentrations. If diabetic
animals are fasted for a few hours with water ad
libitum, normal glucose levels are regained, but the
animals still present reduced responses to the
irritants. Accordingly, insulin deficiency, more than
hyperglycaemia, is likely to be the cause of oedema
inhibition in diabetic animals.42’4 Diabetes mellitus
does not affect the endogenous release of vasoactive
agents, as referred to above. Furthermore, equi-
valent in vitro release of histamine from mast cells
or of kinins from plasma by specific releasing agents
is observed irrespective of whether the cells or
plasma are obtained from normal or diabetic
animals. In addition, diabetic animals exhibit
decreased responses, in comparison with controls,
to permeability factors such as histamine, bradyki-
nin, or serotonin injected into the skin. Therefore,
even if an irritant is capable of releasing
permeability factors in diabetic animals, the ultimate
effect of such factors on the microvasculature of the
affected area is decreased, thus suggesting a
modulatory role for insulin at this level. 42’43
Reduced responses to intracutaneous permeability
factors are also observed in normal animals
previously given 2-deoxyglucose to inhibit glucose
utilization. Insulin does not improve the response
of 2-deoxyglucose treated animals to the per-
meability-increasing agents.
2 The fact appears to
indicate that whenever glucose utilization by the
reacting structures is impaired, reduced micro-Hormones and injqammation
vascular permeability responses can be observed.
The activity of vascular endothelial cells may,
therefore, be metabolically regulated by insulin.
Activation of sensory neurons in unmyelinated
fibres results in arteriolar dilatation and plasma
exudation. The response is known as neurogenic
inflammation and presumably involves the release
of substance P and related substances. Neurogenic
inflammation is also reduced in alloxan diabetic
rats.
43 Furthermore, a marked decrease in plasma
leakage evoked by substance P is observed in rats
rendered diabetic by the administration of strepto-
zocin. Determination of the content of substance P
in sensory nerves and spinal ganglia, however,
44 shows that it is not altered by the diabetic state.
In contrast with the observations described
above, altered transendothelial changes with
diffusion of serum proteins to perivascular tissues,
particularly at the capillary level of the microcircula-
tion, may accompany the progression of the diabetic
state. These changes, however, are not ’inflam-
matory’ in their nature but rather reflect the
occurrence of metabolic disorders responsible for
the development of the diabetic microangiopathy.
Recent evidence indicates that the endothelial cell,
via specific receptors, is capable of responding to
nonenzymatic glycosylation products originating
from the interaction of simple sugars with amino
groups. Nonenzymatic glycosylation is enhanced in
patients with diabetes mellitus. When glycosylation-
modified albumin is added to cultured endothelial
cells, an increased permeability is observed.
Accordingly, extravasation of serum proteins in
diabetic vascular disease, unrelated to inflammatory
stimuli, at least in part, appears to depend on the
response of endothelial cells to glycosylation end
products.
45
Insulin receptors in inflammatory cells: In white cells, the
insulin binding can be studied under conditions that
are most nearly physiological, employing normal
ceils or cells obtained from patients with clinical
disorders. Furthermore, cultured cells can also be
used. Granulocytes, mononuclear leukocytes, gran-
ulocytic leukaemic white cells, cultured human
lymphocytes--and human erythrocytes and cul-
tured fibroblasts as well--all have specific insulin
binding sites. These cells bind 12sI-insulin, and the
bound hormone is displaced by nanogram quanti-
ties of unlabelled peptides.
46-5 When freshly
isolated circulating leukocytes (monocytes) are
incubated with 1251-insulin and examined by
electron microscopic autoradiography, about 20%
of the labelled material is internalized after 15 min
at 37C. By 2h at the same temperature,
approximately one-half of the 125I-insulin is
internalized. The leukocytes bind and internalize
insulin in a manner that mirrors that of major target
tissues, such as the hepatocytes,
sl Since cell surface
receptors are internalized with the ligand, this
provides a mechanism to initiate cell surface
receptor loss. After removal of insulin from the
incubation medium, the internalized receptors are
rapidly reinserted back into the cell surface, s2
Accordingly, the concentration of available insulin
receptors on the cell surface and, consequently, the
sensitivity of the cell to insulin, are regulated by
the ambient concentration of insulin.
Cultured macrophages and macrophage-contain-
ing cell populations both possess specific receptors
for insulin with properties indistinguishable from
those of human leukocytes and other mammalian
tissues, s3 In addition, platelets contain specific
receptors for insulin,s4 Therefore it is entirely
possible that a variety of functions of circulating
leukocytes and platelets and of tissue macrophages
are under the influence of insulin.
Studies on polymorphonuclear leukocytes ob-
tained from diabetic patients greatly enhanced the
knowledge of the role played by insulin in
metabolic functions of inflammatory cells. The
available evidence points towards glucose being
freely permeable to the cell membrane. Comparative
investigations show that the glycolysis of diabetic
cells is decreased relative to controls. Glucose-6-
phosphate and fructose-6-phosphate accumulate in
diabetes, suggesting a decreased activity of
phospho-fructokinase. The increase in glucose-6-
phosphate concentration is probably responsible for
the decrease in glucose utilization. The amount of
glycogen and its synthesis is markedly reduced in
diabetes. Insulin in vivo corrects the metabolic
alterations observed in polymorphonuclear leuko-
55 cytes.
Abnormalities of leukocyte functions in diabetes mellitus: An
enhanced susceptibility to infection is thought to
occur in a poorly controlled diabetic state. In
addition, critical evaluations of the topic show that
infection is more serious and possibly more difficult
to eradicate in the diabetic host. s6,s7 This might
reflect an altered capacity of the diabetic patient to
mount an inflammatory response, and the occur-
rence of immunoregulatory disorders.
Granulocyte dysfunction is a common finding in
diabetes mellitus. Investigations in well-controlled
diabetic subjects may fail to demonstrate any
consistent defect that might predispose the patient
to infection. However, in poorly controlled diabetic
states, and in experimental diabetes mellitus,
abnormalities in granulocyte chemotaxis, phagocyt-
osis and microbicidal mechanisms are described.
Disturbances of the inflammatory cycle evoked
by diabetes mellitus with reduction of leukocyte
migration to the inflamed lesion are not uncommon.
They have been clinically recognized,
s8 For
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instance, the early granulocyte phase of the local
cellular response in surgically abraded lesions is
significantly delayed and diminished in poorly
controlled diabetic patients,
s9 Furthermore, the
mean chemotactic index in diabetic patients is
significantly less than in matching controls. The
defect in chemotaxis is not correlated with plasma
glucose levels, serum carbon dioxide, and blood
urea nitrogen values.
6-63
The early local exudative cellular reaction in an
inflammatory lesion is impaired in alloxan-induced
diabetic rats due to a reduced migration of
neutrophils to the inflamed area. Neutrophils,
however, are capable of moving from reserve
compartments (inflammatory leukocytosis) into
blood in these animals, as much as in controls.
Furthermore, an intrinsic cellular defect does not
occur, because leukocytes obtained from diabetic
animals are not devoid of chemotactic responsive-
ness when suspended in culture medium or normal
serum. Suspended in the corresponding ’diabetic’
serum, blockade of chemotaxis to lipopolysacchar-
ide (LPS)-activated serum is observed. Hypergly-
caemia alone, or hyperosmolality secondary to
hyperglycaemia, the presence of ketone bodies,
malnutrition, or a direct effect of alloxan do not
explain the results. In addition, the capacity to
generate chemotactic agents remains intact in serum
of diabetic animals. The defect appears to be due
to the presence of an inhibitory factor in plasma
which is heat labile (56C), is destroyed by
incubation with trypsin, and is retained after dialysis
with 10 000 Mr retention dialysis tubing. Pretreat-
ment of the animals with insulin results in the
recovery of the chemotactic response either in vitro
or ill vivo.
64 The inhibitory activity of chemotaxis is
detected shortly after the onset of the diabetic state,
being observed from the third day of alloxan
administration.
6s The neutrophil migratory re-
sponse in vitro to the chemotactic peptide
N-formyl-methionyl-leucyl-phenyl-alanine (fMLP),
and to leukotriene (LT) B4 is not affected by the
presence of diabetic rat serum. 66 Bacterial lipopoly-
saccharides have been demonstrated to activate
both the classical and the alternative pathways of
complement by a mechanism that does not require
antibody to the LPS molecules. This results in the
rapid appearance of chemotactic activity. Distinct
subsets of chemotactic receptors mediate the
response of neutrophils to fMLP, LTB4 and
complement-derived chemotaxins. Accordingly, the
inhibitory activity of chemotaxis developing in
diabetic rat serum appears to be restricted to some
stage of the interactive process between neutrophils
and complement-derived chemoattractants.
The mechanisms underlying leukocyte accumula-
tion in a tissue depend on the interaction between
the cells and the vascular endothelium. The contact
between white cells and the vessel wall, particularly
in venules, may take the form of either rolling of
leukocytes along the endothelium or their sta-
tionary adhesion. If adhesive forces are sufficient to
fully counter the shearing forces exerted by the
blood stream, then stationary leukocyte adhesion
will result. In the case of lesser adhesive forces,
leukocyte rolling may occur, provided the shearing
forces remain below a critical level.
67 During
inflammation leukocyte-endothelial interactions
progress to a point where adherence and emigration
of the cells occur. Defective leukocyte-endothelial
interactions are observed in situ in diabetic states.
Under basal conditions, the number of rolling cells
in postcapillary venules of transilluminated tissues
of diabetic rats is markedly reduced relative to
controls. The finding is not dependent on the
number of circulating leukocytes because total and
differential counts in the peripheral blood are
equivalent in both groups. If a noxious stimulus is
applied to induce a local lesion, leukocytes
accumulate in the connective tissue of normal
animals in a pattern characteristic of the inflam-
matory reaction, whereas in diabetic rats only a
few cells are found in an equivalent area of the
perivascular tissue. Reversal of the defective
leukocyte-endothelial interaction is attained by
treatment of diabetic animals with insulin. Control
rats injected intravenously with lyophilized plasma
constituents, obtained after dialysis of diabetic rat
plasma with 12 000 M retention dialysis tubing,
behave as diabetic animals in that they exhibit a
reduced number of leukocytes rolling along the
venular endothelium. Heating of active samples for
1 h at 56C results in the complete loss of the
inhibitory effect.
68
The findings indicate that substances present in
plasma of diabetic subjects are capable of
influencing leukocyte-endothelium interactions and
chemotaxis, thereby reducing the number of cells
which accumulate in an inflamed area. What is still
incompletely defined is the precise nature and origin
of these substances. Several families of adhesion
receptors which play a role in leukocyte-endothelial
interactions and, possibly, chemotaxis have been
identified. These include: the integrins; the
adhesion molecules of the immunoglobulin super-
family; and cell adhesion molecules with lectin-like
domains.
69 Disturbances of the inflammatory cycle
evoked by diabetes mellitus--and characterized by
a reduced leukocyte migration to the inflamed
area--might ultimately reflect an interference of
plasma factors on the activity of such receptors.
Much effort has gone into studies of the
phagocytic and microbicidal function in diabetes
mellitus and, with a few exceptions, results reveal
impairment of these functions. The percentage of
neutrophils actively engaged in phagocytosis is
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considerably less in diabetic rats and the average
number of organisms which have undergone
phagocytosis by these cells is reduced relative to
cells of normal control animals. However, the
differential cell counts of the peripheral blood of
the alloxan diabetic rats are equivalent to those of
controls.
7 In addition, alloxan diabetic rats are
more susceptible to experimental pneumococcal
pneumonia than nondiabetic rats. The cumulative
mortality in the diabetic group is significantly
higher and more than ten times as many viable
pneumococci are found in the pneumonic lesions of
these animals as are present in the lesions of the
nondiabetic controls. Serial histological studies
revealed that phagocytosis is strikingly depressed in
the alveolar exudates of the diabetic animals.71
To separate ingestion from killing in ’diabetic’
granulocytes, a technique was developed which
distinguishes whether the altered efficiency of
microbial killing is a consequence of an impairment
in intracellular mechanisms or simply a consequence
of a slower rate of microbial ingestion. From these
studies it was concluded that diabetic subjects have
a neutrophil phagocytic defect, an impaired
intracellular killing, or a combined phagocytic and
intracellular killing defect.72 Since a clear-cut
improvement in the microbicidal function of
granulocytes is achieved following intensive dia-
betes management and reduction of fasting glucose
concentrations, insulin may also participate in
metabolic pathways regulating intracellular micro-
bial killing. Glucose is freely permeable to the
polymorphonuclear membrane. Most glucose,
however, is metabolized via the glycolytic pathway
and some enzyme reactions in this pathway are
closed regulated by insulin availability. This
suggests that the impairment in microbicidal
functions in diabetes mellitus may have a metabolic
basis.73
Diabetes mellitus may also affect the mono-
nuclear phagocytic system. Macrophages obtained
from the peritoneal cavity of alloxan diabetic rats
exhibit a reduced capacity to engulf opsonized
sheep erythrocytes when compared with the activity
of cells obtained from matching controls. Recovery
of the impaired response is attained by pretreatment
of the animals with insulin.65
Immune responses: With the use of monoclonal
antibodies to characterize lymphocyte subsets it was
suggested that patients with type-I (insulin-
dependent) diabetes mellitus may present immuno-
regulatory disorders already at the onset of the
disease due to quantitative imbalance oflymphocyte
subsets. In type-I diabetes of long standing the total
T-cell population is reduced. Type-II (noninsulin-
dependent) diabetic patients, however, show no
abnormalities in T-lymphocyte subsets,v4 Sup-
pressor T-cell activity is reportedly defective when
lymphocytes from insulin-dependent diabetic pa-
tients are stimulated by concanavalin A. The
abnormality may be related to a paucity of
suppressor T-lymphocytes as evaluated by specific
monoclonal antibodies.75-78 Cell-mediated immune
responses are significantly reduced in human
insulin-dependent diabetes,
79 as well as the
production of IL-2. 8’81
Comparison of antibody responses in normal and
diabetic animals has not always conclusively
revealed a significant difference between both
groups.
2 Diabetic and control rats sensitized by the
subcutaneous injection of a solution of ovalbumin
exhibit equivalent IgE antibody titres, as measured
by homologous passive cutaneous anaphylaxis.
However, a marked reduction in the number of
leukocytes present in the bronchoalveolar lavage
fluid after antigen challenge is observed in diabetic
animals. Pretreatment with insulin restores the
response to normal levels. The finding implies that
despite equivalent antibody production, sensitized
diabetic animals are unable to react normally to
antigen challenge, and that the impaired response
is likely to depend on the continuing deficiency of
insulin associated with the diabetic state.
83
Conclusions: Overall, the experimental findings com-
mented upon in the preceding sections agree with
Table 1. Evidence supporting the proinflammatory effect of insulin
Reference no.
Occurrence of specific receptors on the surface of endothelial and inflammatory cells.
Quantitative alterations of inflammatory events in insulin-deficient states:
(a) Decreased microvascular responses to inflammatory mediators;
(b) Reduced microvascular leakage and oedema formation;
(c) Deficient leukocyte-endothelial interactions arid reduced accumulation of cells in inflammatory exudates;
(d) Granulocyte dysfunctions characterized by chemotactic, phagocytic and intracellular killing defects;
(e) Impaired function of the mononuclear phagocytic system.
Restorative effect of insulin unrelated to the correction of hyperglycaemia and plasma osmolality (in
insulin-deficient states).
Enhanced susceptibility to infection in patients with diabetes mellitus; infections are more serious and possibly
more difficult to eradicate.
19-21,46-53
29,30,32,34,35
36,42-44
59,68
60-64,66,70-72
65
29,30,32,34,36,
42,43,64,65,68,83
56,57
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the clinical evidence that disturbances of the
inflammatory cycle are not uncommon in the
diabetic state, rendering the diabetic patient more
susceptible to infections. Under normal conditions
the activity of the pancreatic islet B cells supplies
optimal concentrations of circulating insulin which
is then immediately available to target structures.
Insulin receptors can be identified in the reacting
structures of an inflamed area. It is plausible,
therefore, to assume that the activity of those
structures is under control by the ambient
concentration of the hormone. Altered vascular
responsiveness, defective leukocyte-endothelial in-
teractions, and inflammatory cell dysfunctions
resulting in chemotactic, phagocytic, and intra-
cellular microbial killing defects are described in
insulin-deficient states. In most instances, pretreat-
ment with insulin corrects the alterations observed,
thereby indicating that a continuing deficiency of
the hormone is a major element in conditioning
impaired responses to noxious stimuli. Evidence for
the proinflammatory role of insulin is summarized
in Table 1.
Glucocorticoids and the feedback
mechanism regulating the
progression of inflammatory
responses
The glucocorticoid receptor: The molecular mechanisms
by which glucocorticoid effects are produced have
many common features with those of other classes
of steroids. They readily penetrate the cell
membrane. In the cell the hormone binds to
receptor proteins and exerts its effects through
receptor-mediated genomic actions. From numer-
ous observations, generally it has been concluded
that the uncomplexed glucocorticoid receptor is a
heteromer composed of a single steroid and
DNA-binding subunit, and two 90 kDa heat shock
proteins (hsp90). Such proteins are abundant
cytoplasmic materials. The DNA-binding domain
is a highly conserved sequence of about 65 amino
acids required for interactions with the glucocorti-
cold response elements (GREs), that correspond to
short sequences of DNA to which the receptor
binds to alter transcription. The carboxy-terminal
amino acids comprise the steroid binding domain
that, in the absence of the ligand, appears to
maintain the receptor in a repressed state. Binding
of the hormone to its receptor results in the
formation of a complex that undergoes activation
with acquisition of an enhanced affinity for DNA.
Activation is thought to involve a conformational
change of the hormone-receptor complex with
dissociation of the hsp90 subunits. Translocation
of the activated complex into the cell nucleus
forms the nuclear bound complex, primary effects
of glucocorticoids being exerted at the gene level
and resulting in transcriptional induction or
repression. In humans, the glucocorticoid receptor
is found in nearly all cell types. The molecular
basis for target cell specificity cannot, therefore,
be due to cell-specific expression of the receptor,
but is more likely controlled at the level of the
target gene itself.84-9
Glucocorticoid administration and the sequence of inflammatory
events: Glucocorticoids have long been used for the
management of inflammatory diseases and deleter-
ious immune responses. Steroids employed in
glucocorticoid therapy are usually analogues of
cortisol, the major active glucocorticoid in humans.
Therefore, their administration under experimental
conditions greatly helps the understanding of
glucocorticoid action.
The microcirculation: Glucocorticoids are known to
play a role in the maintenance of the functional
integrity of the microcirculation. Corticosterone
depresses the permeability effects of inflammatory
mediators in normal animals, while the enhanced
permeability response in adrenalectomized animals
is decreased by the steroid to levels somewhat lower
than in controls.
91 Dexamethasone significantly
decreases permeability reactions caused by com-
pound 48/80, calcium ionophore, hypotonic salt
solutions, histamine, serotonin, platelet-activing
factor (PAF), bradykinin and LTC4 and LTD4.
Maximum inhibitory effects are obtained a few
hours after drug administration.
92 Passive cutaneous
anaphylaxis evoked in mice is blocked by
glucocorticoids. A latency period is required for the
expression of the inhibitory elCfect.
92 In addition,
vascular leakage in an inflammatory reaction
induced by immune complexes is counteracted by
the steroids.
93 In exteriorized tissues, local exposure
of the microcirculation to a glucocorticoid blocks
microvascular leakage evoked by histamine or
LTB4. The effect, observed after a latency period,
apparently is exerted at the vascular endothelial cell
level.94’95 Glucocorticoid receptors are demon-
strable in cultured endothelial cells and constitute a
population of high-affinity sites in these cells,
96
where the steroids exert several effects including
changes in morphology and protein synthesis.
9v
Accumulation of leukocytes in inflammatory infiltrates:
Leukocytes always adhere to the vascular en-
dothelium before penetrating the vessel wall. Two
categories of substances formed or released in an
inflamed area enhance leukocyte adherence to
endothelial cells: chemotactic products and cyto-
kines. The effect of chemoattractants (complement-
derived factors, fMLP, LTB4) is primarily directed
towards the leukocyte, since pretreatment of the
endothelial cell with such substances usually fails to
enhance adherence. In addition, cytokines such as
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tumour necrosis factor (TNF) and granulocyte- microbicidal activity are dependent on the con-
macrophage colony-stimulating factor (GM-CSF) centrations used. In vitro, high concentrations of the
also enhance the ability of neutrophils to adhere to steroids are required to block phagocytic functions
the endothelium.98-12 The stimulation is usually and microbicidal capability of polymorphonuclear
transient. Endothelial cells invitroarestimulated by leukocytes. Moderate to severe impairment of
TNF and interleukins (IL) to become more neutrophil phagocytosis occurs when cortisone is
adhesive to neutrophils.
99-13 As referred to above, administered daily to human subjects for 7-9
specific adhesion glycoproteins expressed on the days. In addition, lysosomal membrane stabilization
surface of leukocytes and endothelial cells play a as measured by the retarded release of acid
relevant role in the adhesive phenomenon, phosphatase, and impairment in aerobic lactate
Chemotactic factors acting on leukocytes and formation and glucose utilization are observed with
cytokines acting on both the leukocyte and the the use of cortisone. Hydrocortisone impairs the
endothelial cell induce the expression of adhesion bacterial capacity of human polymorphonuclear
molecules on their surface favouring cell-to-cell leukocytes, and decreases 02 consumption, the
interactions. IL-1 is produced by nearly all cell types production of H202, glucose utilization, and the
in response to antigens, toxins, and inflammatory extracellular release of granular enzymes by the
processes. It is capable of inducing synthesis of cells. 112’13
other cytokines (lymphokines) arid shares many of In normal mice, hydrocortisone does not alter the
its properties with TNF.4’5 Reduction of serum number of macrophages already present in the
IL-1 activity is observed after treatment with peritoneal cavity, but the transit of mononuclear
glucocorticoids.
16 Glucocorticoids decrease the phagocytes from the circulation into the peritoneal
production of IL-1 by macrophages,
lv Treatment cavity is arrested. However, during an inflam-
of human lung fragments in vitro with glucocorti- matory response in the peritoneal cavity, hydro-
coids results in a dose-dependent inhibition of IL-1 cortisone is able to suppress the increase in
production. Nonglucocorticoid steroids have no number of peritoneal macrophages. This effect
effect.
8 Glucocorticoids strongly inhibit TNF appears to be due to a diminished influx of
production. The inhibiting effect may be demon- mononuclear phagocytes from the peritoneal blood.
strated in vitro in the presence of cortisol Hydrocortisone, however, was found to have no
concentrations corresponding to normal free effect on phagocytosis by mouse peritoneal
cortisol levels in vivo.
is Since locomotion of macrophages.2’113
leukocytes in response to a chemical gradient of
chemotactic factors is thought to remain unaffected Leukocyte kinetics: Because glucocorticoids are capable
following exposure of the cells to glucocorti- of affecting the kinetics of circulating leukocytes,
coids,
19 the steroids, at least in part, appear to their adminstration causes marked changes in blood
inhibit leukocyte accumulation in an inflamed area leukocyte counts. Administration of glucocorti-
by blocking the production of mediators, particu- coids leads to a decrease in the number of
larly cytokines, involved in the recruitment process, lymphocytes, monocytes, eosinophils, and baso-
The steroids might also inhibit the expression of phils in the blood, whereas the number of
adhesive molecules on the surface of inflammatory neutrophils increases.
and endothelial cells. There are considerable differences in suscept-
Both hydrocortisone and betamethasone have a ibility to glucocorticoids among various species.
suppressive effect on neutrophil mobilization into Although the basis of these differences is not clearly
the peritoneal cavity of mice and rats iniected with understood, animal species have been divided into
living microorganisms, endotoxins, or bacterial steroid-sensitive (hamster, mouse, rat, rabbit) and
extracts. Betamethasone also decreases by more steroid-resistant (monkey, guinea-pig, humans)
than 50% the number of neutrophils which are groups. The differentiation is usually based on the
mobilized into the pleural cavity of rats injected relative ease of producing lymphoid depletion after
with kaolin. Several anti-inflammatory steroids are a given regimen of systemic glucocorticoids. In
capable of reducing leukocyte emigration into the addition, there is a heterogeneity in the response of
pouch fluid when tested by suspending them lymphoid cells to glucocorticoids even within the
directly in the irritant solution employed to produce same species.
14
the response. Labelled leukocytes previously In steroid-sensitive species lymphocytopenia
incubated with hydrocortisone and transferred to results from a significant lympholytic effect of the
untreated recipients fail to accumulate at the glucocorticoids. Apparently, the lympholytic effect
inflamed site.1’111 is a receptor-mediated event.
114 In resistant species,
the decrease in number of circulating lymphocytes
Phagocytosis and microbicidalactivity: In many instances, involves redistribution of the cells from the
the effects of glucocorticoids on phagocytosis and circulation into other body compartments. Even
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suprapharmacological concentrations of glucocorti- lymphocytes. The cell-mediated response is am-
coids are not capable of inducing lymphocyte lysis plified by yIFN, that enhances the processing of
in humans. 114’115 Both T- and B-cells are depleted antigen by macrophages.
14
from the circulation, but there is a relative greater Suppression of antibody production by gluco-
effect on the T-cell as compared to other corticoids can be observed in some species,
14 but
lymphocyte subpopulations.1s’6 A transient in humans, where blockade of immunological
monocytopenia with a return to normal counts reactions by glucocorticoids has been described, it
within approximately 48 h, and eosinopenia occur appears to have no accompanying effect on antibody
in sensitive and resistant species following gluco- synthesis.4’6 Patients on glucocorticoid therapy
corticoidadministration. The responseisapparently exhibit a nearly normal antibody response to
dependent on redistribution of the cells.
1 Steroid- antigenic challenge.
7 Furthermore, there is no
induced neutrophilic leukocytosis reaches a peak convincing evidence at present to suggest that
4-6 h after drug administration. The response is glucocorticoids directly affect the complement
thought to occur mainly by an enhanced mobiliza- system.
8 Glucocorticoid therapy does not sig-
tion of cells from the marginated granulocyte nificantly suppress the immediate wheal-and-flare
pool.
12 Neutrophilia induced by glucocorticoids response to an antigen skin test in atopic patients,
resembles peripheral blood changes produced by thus suggesting that histamine release is not altered
epinephrine and exercise. In’these circumstances, by the steroids.
18
the time to achieve peak responses is short, the Monocytes and macrophages are among the most
neutrophil alkaline phosphatase content of cells is sensitive cells to the actions of glucocorticoids,
low which may signify re-entry or shifting of older whereas the lymphocyte is relatively resistant.
mature cells from the marginated pool, and the Inhibition of recruitment of macrophages to an
number of immature cells in the peripheral blood affected area is achieved by the use of glucocorti-
remains low. Following administration of gluco- coids. Though production of macrophage mi-
corticoids the time to peak neutrophilia is also gration inhibitory factor (MIF) by sensitized
relatively short; the alkaline phosphatase content lymphocytes is not affected, the effects of MIF on
that is inversely related to neutrophil age is macrophages are blocked by glucocorticoids.1<119
normally reduced in released cells; and immature Antigen uptake by macrophages is not influenced
neutrophils in the peripheral blood are practically by the steroids.9 However, the facilitatory effect
absent. These findings corroborate the suggestion of ylFN on the processing and display of antigens
that development of neutrophilia following gluco- is inhibited. This suggests that activation of
corticoid administration is primarily due, at least in macrophages is regulated by opposing actions of
humans, to mobilization of the marginated granul- cytokines and glucocorticoids. In addition, gluco-
ocyte pool.
2 corticoids decrease the production of IL-1 as
referred to above. Two distinct forms of IL-1,
The immune system: In many instances, undesirable termed IL-10 and IL-lfl, have been purified and
consequences of an antigenic challenge can be cloned. Production of both forms of IL-1 is
controlled by the use of glucocorticoids. The suppressed by the steroids in a dose-dependent
control is chiefly the result of glucocorticoid effects fashion and this is accompanied by equivalent
on cytokine production or cytokine actions, reductions in mRNA expression for IL-1.12
An antigen processed by the macrophage is Accordingly, glucocorticoids through inhibition of
presented to resting T-cells together with a major IL-1 production are capable of influencing
histocompatibility antigen. Under the influence of activation of resting T-cells. Furthermore, gluco-
IL-1, secreted by the macrophage, the resting T-cell corticoids reduce the generation of IL-2 and inhibit
becomes activated and synthesizes a variety of expression of IL-2 receptors on T-lympho-
proteins, of which some are released and others cytes.
2q23 Therefore, T-cell proliferation is effect-
become integral components of the cell membrane, ively blocked by the steroids, since IL-2 directs
Gamma-interferon (2-IFN), IL-2,-3 and-4, as well clonal expansion of specific T-lymphocytes. A
as the B-cell differentiating factor (BCDF) are direct consequence of these effects is the attenuation
released. Receptors for IL-2 and other cytokines are of cell-mediated immune responses.
examples of membrane-associated proteins gen-
erated during antigenic challenge. The antigen can Endogenous glucocorticoids and the control of injqammatory
also activate B-cells through surface antibodies, responses: Increased blood concentrations of gluco-
B-cells under the influence of 2IFN, IL-1, -2 and corticoids are observed after injection of en-
-4, and BCDF become antibody-secreting plasma dotoxins. This increase results from an enhanced
cells. Activated T-cells undergo clonal expansion release of steroids by the adrenal gland rather than
under the influence of IL-2, that also activates a from decreased metabolism of the normally secreted
particular group of cells to become cytotoxic adrenal steroids.24 Hypophysectomy abolishes the
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adrenal cortical responses to endotoxins, thereby
implying that endotoxins do not act directly upon
the adrenal cortex. Since blockade of the
hypothalamic release of corticotropin-releasing
hormone (CRH) also abolishes the increase of
plasma glucocorticoids resulting from the injection
of endotoxins, the substances appear to cause an
increase of plasma corticosteroids by an action on
the hypothalamus-pituitary-adrenal axis at the level
of the nervous system.
During the early stages of experimentally induced
inflammatory responses, blood levels of glucocorti-
coids are consistently and markedly increased.
126-28
Evidence has been obtained that the development
of acute inflammatory responses is regulated by a
feedback mechanism which is induced compara-
tively early. In carrageenan or dextran lesions of the
rat’s paw, a factor has been harvested in perfusates
of lesions 2-3 h in age, though not less than 1 h
old. The effects of the factor are demonstrable by
a decrease of exudation in other animals given the
perfusate intravenously prior to injection of an
irritant into the paw. Inhibition of oedema
formation is abolished by prior adrenalectomy or
electrolysis lesions in the hypothalamic median
eminence of the test animals. The perfusate also
elevates the serum level of corticosterone, con-
comitantly depressing the content of ascorbic acid
of the adrenal. On the other hand, the perfusate is
effective in rats whose adrenal medulla has been
ablated, suggesting that adrenal catecholamines play
no significant role in the inhibitory effect.
Accordingly, the factor harvested in perfusates
from inflamed lesions seems to owe its effects to the
release of glucocorticoids (corticosterone) via the
hypothalamus-pituitary-adrenal axis. In addition,
when both hind paws of the rat are injected
simultaneously with an irritant, responses of the
same magnitude and parallel time-course develop-
ments are observed. If the injections, however, are
made at an interval of 2.5 h, the paw that is first
injected exhibits a normal response, whereas the
response in the other paw is reduced to about 50%.
This attenuation is not observed in adrenalecto-
mized animals. These data have been interpreted to
indicate that glucocorticoids secreted in larger
amounts during the early stages of an inflammatory
reaction, apparently govern the development of
such reaction. The increased secretion, induced via
the hypothalamus-pituitary-adrenal axis under the
influence of factors produced in the inflamed area
would thus represent the last event of a feedback
mechanism that regulates the progression of
inflammatory responses.
26 More recent invest-
igations support the occurrence of a regulatory
mechanism governing the development of inflam-
mation. First, a relationship between the temporal
development of carrageenan-induced inflammatory
lesions and pulsed release in plasma of increased
amounts of corticosterone in rats was reported.
I28
Secondly, it was shown that susceptibility of inbred
Lewis female rats to develop arthritis in response
to streptococcal cell wall peptidoglycan poly-
saccharide (SCW) was related to a defective
hypothalamus-pituitary-adrenal axis responsive-
ness to inflammatory mediators.
129 Thirdly, it
was observed that resistance of histocompatible
Fisher rats to SCW arthritis is regulated by an intact
hypothalamus-pituitary-adrenal axis-immune sys-
tem feedback loop.
29
IL-1 provokes the secretion of adrenocortico-
tropic hormone (ACTH) and corticosterone in mice
and rats.13 Immunoneutralization of CRH blocks
the stimulatory effect of IL-1 on glucocorticoid
secretion, pointing to an activation of CRH
secretion in response to the cytokine.
TM Similarly,
IL-6 stimulates the secretion ofACTH in conscious,
freely moving rats. The effect can be abolished by
a previous injection of antiserum against CRH,
thereby indicating that one site of action of IL-6 is
at the hypothalamic level. Accordingly, a mutual
regulatory control mechanism occurs between the
reacting structures in an inflamed area and the
activity of the hypothalamus-pituitary-adrenal
axis.
32 The regulatory mechanism apparently
involves the participation of cytokines generated at
the inflamed site.
Inflammatory cell functions are also markedly
influenced by the level of circulating glucocorti-
coids. The number of leukocytes rolling along the
venular endothelium of the microcirculation
network is markedly increased in adrenalectomized
rats relative to sham-operated and normal controls.
Blood leukocyte counts, however, are equivalent in
the three groups of animals. No noticeable
haemodynamic changes occur to explain the
increase in number of rolling leukocytes in
adrenalectomized rats. The rolling movement that
represents the primary leukocyte-endothelial inter-
action, is presumably the result of two forces, one
an adhesive force towards the wall of the vessel and
the other the shearing force of the flowing blood.
In a given venule with approximately constant
blood flow velocity the shear force also remains
constant.
13 Adhesion changes affecting the primary
leukocyte-endothelial interaction are likely, there-
fore, to prevail following the ablation of the adrenal
glands, resulting in an increased number of rolling
leukocytes. That the effect is under control by
glucocorticoids is indicated by the fact that
methyrapone-treated animals also exhibit an en-
hanced number of cells rolling along the venular
endothelium. Methyrapone, through inhibition of
the 11-/3-hydroxylation reactions in the adrenal
cortex, markedly reduces the secretion of cortisol,
corticosterone and aldosterone, while the secretion
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of 11-deoxycorticosteroids is relatively unimpaired.
Accordingly, tle administration of methyrapone
results in a compensatory increase in the secretion
of ACTH and in enhanced secretion of 11-
deoxycortisol, a relatively inert steroid, and
11-deoxycorticosterone, a mineralocorticoid.
Therefore, methyrapone blocks the production of
glucocorticoids but does not typically cause a
deficiency of mineralocorticoids.
Under the influence of local inflammatory
stimuli, cells emerge into the perivascular tissue.
The number of cells, chiefly neutrophils, present in
a standard area in the tissue is greater in
adrenalectomized than in control animals. Endo-
genous glucocorticoids, therefore, appear to control
leukocyte migration to an inflamed area through
an interference with leukocyte-endothelium inter-
actions.
6s Adhesion glycoproteins of the integrin
family (f12 integrins), collectively termed CD11/
CD18 complex, 134’13s are only expressed in haema-
topoietic precursor cells and in white blood
cells. The complex is composed of ofl glycoprotein
heterodimers with distinct o chains (CD11a,
CD 1 lb, CD 1 lc), and a common fl subunit (CD18).
Administration of a monoclonal antibody anti-
CD18 to adrenalectomized rats completely blocks
the previously enhanced migration of leukocytes
from the microcirculation to the perivascular
inflamed tissue. The finding suggests that gluco-
corticoids may govern the expression or the activity
of the CD11/CD18 complex on the surface of
leukocytes, thereby limiting the migration of these
cells to inflamed areas.
Glucocorticoids vs insulin: A possible interrelationship
may exist between endogenous glucocorticoids and
insulin in controlling the development of acute
inflammation. 127 Insulin appears to facilitate the
action of vasoactive substances on vascular
endothelial cells, thus contributing to the formation
of interendothelial gaps and to increased vascular
permeability to plasma proteins. The activation of
the hypothalamus-pituitary-adrenal axis by factors
formed in inflamed tissue results in increased levels
of circulating glucocorticoids which, in turn, are
relevant for the maintenance of the integrity of the
microcirculation. The immediate opening of the
endothelial intercellular junctions at the venular
side of the microvasculature produced by inflam-
matory stimuli is a transient event, even in the
continuous presence of permeability-increasing
agents.
137 It is plausible, therefore, to suggest that
increased concentrations of circulating glucocorti-
coids, as observed during the early stages of the
inflammatory response, might antagonize the
facilitatory effect of insulin upon endothelial cells
of the reacting vessels, thereby limiting the
development of the response.
Lipocortins: Lipocortin has been described as a
glycoprotein whose synthesis or secretion is
stimulated by glucocorticoids through receptor-
mediated actions and which specifically inhibits
phospholipase A2 in vitro and in vivo.
8 It is now
known that this substance belongs to a much larger
class of proteins which share the property of
binding membrane phospholipids in a calcium-
dependent manner. Due to inhibition of the
phospholipase A2 activity, a controlling enzyme in
the production of eicosanoids and PAF, lipocortins
have been suggested to act as mediators of the
anti-inflammatory effect of glucocorticoids. More
recently, the relevance of the inhibitory action of
lipocortins on phospholipase A2 activity has been
questioned.19’4 Lipocortins are thought to act
extracellularly and must, therefore, be secreted but
there is no direct evidence that they are, in fact,
secreted proteins and it is not known whether they
act as inhibitors of intracellular phospholipase.
Purified lipocortins block the stimulated release of
arachidonic acid from membrane phospholipids,
but not basal release. It is not clear whether any of
the recombinant or otherwise structurally char-
acterized lipocortins are actually induced by
glucocorticoids particularly in a way that correlates
with anti-inflammatory activity. However, the
possibility has been raised that certain proteins can
be secreted by pathways other than those involving
the trans-Golgi network. Following the recent
discovery of putative receptors on phagocytes for
lipocortins (lipocortin-1), and the observation that
these receptors influence the inflammatory actions
of the cells by mechanisms independent of
inhibition of phospholipase A2 activity, a novel
interpretation for the role of lipocortins on
inflammation has been proposed. Activation of the
hypothalamus-pituitary-adrenal axis by potential
mediators, including interleukins and TNF, during
the early stages of the inflammatory response would
result in an enhanced secretion of glucocorticoids,
as referred to above. This in turn, would lead to
the production of lipocortins at discrete sites
throughout the body. Saturation of lipocortin-
binding sites in phagocytes would then reduce the
migratory and proinflammatory activity of these
cells with a consequent downregulation of the host
response.
4 Apparently, even physiological levels
of lipocortin 1 in the absence of inflammation are
regulated by glucocorticoids.
142
The anti-inqammatory action of glucocorticoids: molecular
mechanisms: As for most biological et:fects of steroids,
the anti-inflammatory activity of glucocorticoids
involves receptor occupancy and induction of gene
expression. The molecular mechanisms underlying
this activity were established by two lines of
evidence. One derives from experiments in-which
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Table :). Evidence for the role of glucocorticoids as modulators of inflammatory responses
Reference no.
Occurrence of specific receptors in endothelial and inflammatory cells.
Increased concentrations of circulating glucocorticoids at the early stages of inflammation resulting in
downregulation of inflammatory responses.
Enhanced microvascular responses to inflammatory mediators and increased migration of cells to
inflamed areas in adrenalectomized animals.
Potent anti-inflammatory and immunosuppressive effects following exogenous administration:
(a) Reduction of cytokine production or activity;
(b) Decreased microvascular responses to inflammatory mediators;
(c) Inhibition of leukocyte accumulation at inflamed sites;
(d) Blockade of phagocytic functions and impairment of microbicidal capacity of polymorphonuclear
leukocytes;
(e) Inhibition of recruitment of mononuclear phagocytes to injured areas;
(f) Interference with leukocyte kinetics;
(g) Interference with the activity of the immune system.
96,97,114,143,145,146
126-128
65,91,126
105-108,120-123
91-95
110,111
112,113
112,113
112,114-116
114,116,119,121-123
inhibition of RNA and protein synthesis were used
to study the effects of dexamethasone. The existence
of a time lag for manifestation of the anti-
inflammatory effect of the steroid was interpreted
to represent time required to bring about
production of specific proteins through gene
expression. The effect is suppressed by actinomycin
D or cycloheximide, thereby indicating that RNA
and protein synthesis are essential for the expression
of the anti-inflammatory activity of the glucocorti-
coid.
143 The other line of evidence is based on the
effects of RU38486, a synthetic glucocorticoid
receptor antagonist. The substance exhibits a high
affinity for the corresponding receptor and displays
antiglucocorticoid activity in vivo and in vitro. 144
Treatment with RU38486 blocks, in a dose-
dependent manner, the anti-inflammatory eect of
dexamethasone under various experimental condi-
tions, confirming that this action, like most steroid
actions, occurs by receptor-mediated proces-
145,146 ses.
Conclusions: Glucocorticoids are potent anti-inflam-
matory agents and have long been used as
valuable medications in the management of a
variety of diseases. Usually, analogues of cortisol,
the prevalent glucocorticoid in humans, are
employed in glucocorticoid therapy. In the last two
decades evidence has been obtained that the
self-limiting character of inflammatory responses is
associated with increased plasma concentrations of
the steroids. The increased secretion, induced via
the hypothalamus-pituitary-adrenal axis by puta-
tive inflammatory mediators, represents the last
event of a feedback mechanism that regulates the
development of inflammation. Glucocorticoids are
relevant for the maintenance of the functional
integrity of the microcirculation, and exert
profound effects on inflammatory cell functions.
Furthermore, they apparently govern leukocyte-
endothelial interactions in inflammation and the
subsequent migration of haematogenous cells to
perivascular inflamed tissues. Evidence supporting
the involvement of glucocorticoids in the control
of inflammation is summarized in Table 2.
Oestrogens
Granuloma formation and croton oil-induced
inflammation in experimental animals are lessened
by oestrogen treatment. 147’148 Oestrogens suppress
rat paw oedemas irrespective of the inducer
irritant,
49 and exhibit antipermeability effects on
skin vessels.s Oestradiol consistently diminishes
the incidence of inflammatory joint disease evoked
by adjuvant injected in rats. This protective effect
is apparent over a wide dose range and in a variety
of treatment schedules. Moreover, estimation of the
severity of the arthritis indicates that oestradiol-
treated animals have a much milder disease as
compared with controls. Oestrone and oestriol are
as effective in suppressing arthritis as the parent
compound.s Oestrogens markedly reduce the
cutaneous inflammatory response to tuberculin in
rabbits sensitized by active turberculosis or by
treatment with heat-killed tubercle bacilli. Further,
although oestrogen-treated rabbits develop the
same number of pulmonary lesions after inhalation
of tubercle bacilli, the size of the lesions is
significantly smaller in the treated group.
Oestrogens enhance anti-inflammatory actions of
corticosteroids in the treatment of inflammatory
skin disease in humans. 147
The mechanism through which oestrogens
influence acute inflammation is not clear. A
protecting activity on microvessels which is
independent of a systemic action is suggested, since
the effect is observed by direct application of the
hormones to the target tissue, ls2,s3 This has been
thought to be accomplished through an influence
on acid mucopolysaccharides of the perivascular
ground substance or through the activation of the
adenylate cyclase system that regulates leukocytic
Mediators of Inflammation. Vol 2.1993 193j. Garcia-Leme and S. P. Farsky
lysosomal enzyme release. 154-1s6 The mechanism by
which oestradiol, oestrone and oestriol confer
protection in adjuvant arthritis is also unknown.
Since lymphocytes are involved in the pathogenesis
of this disease, the well-known depleting effects of
oestrogens on lymphoid tissues might account in
part for the protective action of these hormones.
However, the finding that the hormones diminish
the incidence of arthritis when administered in the
latent period either starting on the day of
inoculation, or 5-10 days thereafter, associated with
the fact that the immunological reaction leading to
arthritis is quickly initiated, suggest a direct
hormonal effect on the capacity of involved tissues
to react to the inflammatory stimulus in this
disorder.TM
Oestrogens are reported to influence antibody
formation, and to suppress cell mediated immunity.
In addition, the hormones inhibit lymphocyte
responses to nonspecific mitogens.
Effects of oestradiol and related steroids on
leukocyte function and metabolism in vitro have
been investigated. Human blood leukocytes,
incubated with oestradiol for I h before the addition
of live Staphylococci, ingest the same number of
bacteria as do control leukocytes. The normal
increase in oxygen consumption after phagocytosis,
however, is reduced in the presence of oestradiol.
Cells incubated with oestradiol have diminished
granule lysis after phagocytosis.
s7 Oestrogens,
apparently influence the microbicidal actvity of the
myeloperoxidase system in polymorphonuclear
leukocytes,
ls8 Accordingly, changes in the hormo-
nal environment involving oestrogens may modify
leukocyte responses to inflammatory stimuli.
Further information, however, is required for a
clear interpretation of the way these hormones may
act.
Indirectly acting hormones
Glucagon" Any stimulus of sucient intensity to
constitute a stress and cause a nonspecific increase
in sympathetic efferent activity is likely to
produce a rise in plasma glucagon concentration.
s9
Plasma glucagon levels are elevated in patients with
bacterial infections, in burns, after endotoxin
administration, or following injection of bacterial
pyrogens,
ls9-61 Glucagon interferes with the
development of inflammatory responses. Given
daily by the subcutaneous route, after a local
reaction to Freund’s adjuvant has already developed
in the rat, glucagon produces a decrease in the
response, comparable to that attained with daily
effective doses of indomethacin. Administered
subcutaneously 30 min beforehand, it reduces
oedema formation in the 4-h interval which
follows the injection of chemical irritants into the
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rat’s paw, and decreases the local exudation of
Evans blue previously given intravenously. Appar-
ently this is an indirect effect since it is not
observed in adrenalectomized animals, but persists
after the removal of the adrenal medulla.
1.2 It is
improbable that metabolic changes may play a
role in this circumstance, because increased
insulin secretion can quickly compensate for and
oppose the effects of glucagon.
The investigation of possible effects of glucagon
on inflammatory cells has received limited attention
despite the fact that hormones that influence
carbohydrate metabolism are intimately involved in
the host defence. During the early febrile phases of
bacterial and viral illnesses, fasting plasma con-
centrations of glucose, insulin, glucagon, and even
growth hormone tend to be increased. If
carbohydrate tolerance is measured by means of an
intravenous glucose load at the time, glucose
disappearance rates show changes approaching
those characteristic of maturity onset diabetes.
Furthermore, concurrent hypercortisolism, docu-
mented in clinical studies by increased urinary
excretion of free cortisol during fever, has been
shown to influence glucose tolerance deleteriously
not only through enhancement of gluconeogenesis,
but also through augmentation of glucagon
secretion. .3’1.4 This interplay of hormone actions is
an integral part of the systemic response of the host
against invading microorganisms and may serve a
useful purpose in terms of adaptative metabolic
changes, cell kinetic alterations, and energy supply
during infection. The increased activity of pancrea-
tic islets may reflect, therefore, the need for
homeostatic adjustments in this condition.
Human mononuclear leukocytes specifically
bind glucagon. The molecular basis for the
actions of this hormone in target tissues is the
activation of the adenylate cyclase system in
plasma membranes following the interaction with
specific macromolecular receptors. Elevation of
intracellular concentrations of cAMP appears to
mediate the various physiological actions of
glucagon. Its ei:fects on mononuclear leukocytes,
however, are much less pronounced than in liver
plasma membranes. To date, there is no indication
of a possible involvement of glucagon in the
metabolism of peripheral leukocytes. Therefore, the
significance of its binding to mononuclear leuko-
cytes remains uncertain.*s
Thyroid hormones: Conflicting results have been
obtained from investigations on the influence of
thyroid gland on inflammation. This might reflect
the multiplicity of effects of thyroid hormones on
metabolic pathways, enzyme activities, and on the
response of target tissues to other hormones. In
addition, the age of the animals at which theHormones and inflammation
hormonal disorder is produced and the duration of
the prevailing alteration might be factors in the
variation of the results observed. Nevertheless,
there is evidence to show that altered inflammatory
responses occur in hyperthyroid states.
In an attempt to identify the mechanisms through
which thyroid gland activity can influence the
development of inflammatory reactions, the capa-
city to respond to noxious stimuli was tested in rats
when thyroid defects induced by hormone
administration of thyroidectomy, were fully estab-
lished. Whereas animals kept in a condition of
sustained excess of circulating thyroid hormones
present consistently depressed inflammatory re-
sponses, hypothyroid rats respond in a normal
fashion. 166’167 Decreased reactions to intracutan-
eously injected histamine and serotonin; inhibited
swelling response to carrageendn injected into the
paws; and depressed primary and secondary
reactions to Freund’s adjuvant only occur in the
group of hormone-treated animals. In addition,
enlargement of the adrenal glands; reduced content
of adrenal ascorbic acid; and decreased number of
circulating eosinophils, which characterize a cir-
cumstance of adrenal cortical hyperactivity, are
observed only in this group. A spontaneous reversal
of the previously inhibited acute inflammatory
response to carrageenan occurs 3-4 days after
interruption of hormone administration to the
animals and this is coincidental with the return to
normal of the formerly enlarged adrenal glands.
Similarly, specific inhibition of adrenal cortical
steroid biosynthesis in hormone-treated animals
with aminoglutethimide restores the previously
depressed response to carrageenan without inter-
ference with the increased levels of serum
thyroxine.
167 The findings suggest that the in-
hibitory eects of thyroid hormones on inflam-
matory responses are likely to be indirect.
There are considerable interactions between the
activities of the thyroid gland, the adrenal cortex
and pancreatic islet B-cells. Hypertrophy of the
adrenals and reduced content of adrenal ascorbic
acid are observed following thyroid hormone
administration,
168-17 whereas thyroidectomy or
injection of antithyroid drugs alone may result in
atrophy of the adrenal gland. 171’172 The influence of
thyroid hormones on the activity of the adrenal
gland is either direct or indirect through changes
in the release of ACTH. 173-175 Pancreatic B-cell
dysfunction has been suggested by observations of
decreased insulin secretion in isolated islets from
animals made thyrotoxic, and by either decreased
plasma insulin responses to an intravenous glucose
challenge or lack of increased insulin levels in the
face of hyperglycaemia.
176-178 Such interactions are
a reasonable explanation for the effects of thyroid
hormones on inflammation.
Concluding remarks
Almost any stage of inflammatory and immuno-
logical responses are affected by hormone actions.
Pro- and anti-inflammatory effects are recognized
and this forms the basis for the suggestion that
hormones exert an integrative function on in-
flammation. The effect of a hormone ultimately
depends on its interaction with a receptor, and a
major determinant of this step is the circulating
level of the hormone. Specific hormone receptors
are demonstrable in the reacting structures of an
inflamed area. Endocrine disorders alter host
defences against trauma and infection. Inflamma-
tion, therefore, is a hormone-controlled process.
Consequently, management of inflammatory dis-
eases should take into account the general condition
of the patient in addition to the clinical evaluation
of local signs and symptoms.
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